Drug induced prolonged QT is associated with torsade de pointes (TdP), and therefore has been under a thorough investigation by FDA for the last 10 years. The main focus has been on the rapid delayed outward rectifier potassium current (Ikr) effects on the ECG QT interval. Lately, multi-ion channel effects like late-sodium and calcium currents have also been investigated, and the new ECG parameters like Tpeak-to-Tend (TpTe) and J-to-Tpeak (JTp) have been shown to correlate with multiple ionchannel changes.
Introduction
The adverse cardiac effects by drugs have been a focus of the FDA and drug companies since a series of released drugs were withdrawn from the markets in the 1990s [1] . Since all the drugs withdrawn increased the risk of torsade-de-pointes (TdP) with different levels of blockage of the potassium channel encoded by the human ether-à-go-go related gene (hERG), which is reflected on the heart rate corrected QT interval (QTc) prolongation of ECG, the focus of cardiac safety regulation has been on the measurement of the QT interval changes during clinical trials [2, 3] . However, there are at least 2 major issues with the QT interval: 1) it is a poor surrogate of TdP, since there are other factors besides duration of repolarization playing important roles, like dispersion and occurrence of early after depolarizations; 2) when multiple ion channels are affected by a drug, it is not all reflected on QT interval changes [1] .
Lately there are many efforts trying to find other ECG parameters, especially T wave morphology related parameters. The purpose is to improve the sensitivity and specificity of identifying drug compounds associated with the risk of TdP and other adverse cardiac effects [4] [5] [6] . In order to evaluate the new T wave morphology ECG parameters along with the QT interval, the FDA sponsored a prospective clinical trial with several on-the-market drugs [7] .
In the clinical trial, 22 healthy subjects received a single dose of a selective hERG blocker (dofetilide) and three drugs that also block calcium or sodium (quinidine, ranolazine and verapamil) as part of a five period, placebo controlled cross-over trial. The trial results revealed that T wave morphology changes are directly related to amount of hERG block, but less sensitive to multichannel block. In this clinical study, ranolazine, which blocks both hERG and late sodium currents (InaL), prolonged QTc by prolonging T peak-to-T end interval (TpTe) with no effect on the heart rate corrected J-to-T peak interval (JTp). Since ranolazine is one of the drugs which have significant QTc prolongation but do not cause TdP, the combination of JTp and QT might be useful for differentiating 'good' and 'bad' QT prolongation drugs.
The focus of this study is to simulate the combination of Ikr and InaL ion currents with a previous published computational cell model and whole heart model [8] , and to evaluate JTp, TpTe, and QT changes found in the clinical study.
2.

Methods
The model includes both cell model and forward model.
Cell models
The cell model was based on ten Tusscher's human cell model [9] . The fast potassium channel was added from Fink-Noble model, which used a Markov process to describe the dynamics part [10] . A Late sodium current was then added based on Xia's paper [11] , which takes two gates formulation:
where mL is an activation gate and hL is an inactivation gate. Each of these gates is governed by Hodgkin-Huxleytype equations for gating variables and characterized by a steady-state value (mL, and hL, ) and a time constant ( mL and hL) for reaching this steady-state value, both of which are functions of trans-membrane potential (Vm). 
Forward model
The forward model was developed based on actual scanned 3-D heart ventricles, left and right. A bidomain model-based Finite-Element-Model (FEM) and Boundary-Element-Model (BEM) coupling formulation in the cardiac electric field was used [12] . The formula to solve forward model is divided into 2 parts: inside myocardium and from the heart surface to the torso. For the inside myocardium portion, FEM method is applied to consider the anisotropy of myocardium. From the heart surface to torso, BEM method is applied for higher computational efficiency.
Model simulation design
The model simulation parameters were set to match the FDA clinical trial's experiments [7] . In their patch clamp experiments, dofetilide has about 55% Ikr block at the population's mean maximum concentration (Cmax); Ranolazine has about 26% Ikr block and 21% InaL block at Cmax.
The current modeling set the Ikr and InaL conductance to 6 levels, with level 1 for base level with no block, and level 2-6 have the block percentages as shown in Table 1 . The model simulations were run in 3 batches: 1) only applying Ikr block; 2) only applying InaL block; 3) applying both Ikr and InaL blocks.
ECG measurements
The ECG measurements of JTp, TpTe, and QT were based on a software, QT Guard Plus TM of GE Healthcare, which was designed for cardiac safety clinical trial and repolarization analysis. The module includes the core algorithm of GE's 12SL TM , a widely used multi-lead ECG interpretation algorithm, and a principal-componentanalysis (PCA) based T wave morphology analysis. In the QT Guard Plus, JTp, TpTe, and QT are calculated based on a composite signal of vector magnitude of 12-lead signals [5] .
The end of T wave algorithm is described in [13] , which used the slope of T wave and the area of T wave for the criteria. The peak of T wave was not simply based on the maximum point of T wave, since it is not reliable with plateau of T wave or when notch appears. Instead, a center of T wave plateau region was selected [14] .
Results
The first part of the simulation was to apply Ikr block only based on the setting on the table 1, where InaL block is not applied. Figure 1 -a shows the resulted vector magnitude (VM) lead for 6 levels of Ikr channel block, ranging from 0 to 26%, with each tracing corresponding to one block case. The bottom curve is the base case with 0 block, and the top curve has 26% block. Individual ECG lead, like V3, shows more obvious T wave notch when more significant Ikr blocks were applied. Both V3 and VM leads show significant T wave morphology changes with more flatness on top of T wave, and T wave notches. The QT interval is increased from 386 to 414 msec, JTp is increased from 222 to 238 msec, and TpTe is increased from 72 to 84 msec, as shown in Figure 1 The second batch of simulations applied InaL block only with the setting as shown in table 1, where Ikr block was not applied. Figure 2 shows the plot of VM lead for 6 levels of InaL block, ranging from 0 to 21%, with each tracing corresponding to one block case. The bottom curve is the base case with 0 block, and the top curve has 21% block. We can see that the T wave morphology changes are not as obvious as in hERG block cases above, and that both the JTp and QT intervals are gradually reduced with the increase of InaL block. The third batch of simulations applied both Ikr and InaL blocks as in Table 1 . Figure 3 -a shows the VM lead for 6 simulated cases with the bottom one having no block and top one having 26% block of Ikr and 21% block of InaL. It shows prolonged QT interval and T wave plateau increase.
The T wave notch is more obvious from lead v3. The QT interval was increased from 386 msec to 404 msec, TpTe was increased from 72 to 96 msec, while JTp was slightly decreased from 222 to 216 msec as in Figure 3 
Discussions
The results of our cell-to-ECG model simulations show the effects of Ikr block and InaL block on ECG morphology in general, and the specific effects on the QT, TpTe, and JTp intervals. In order to compare with the FDA clinical trial data, this study was focused on the ion channel block setting from ranolazine's patch clamp experiment with a 26% of Ikr block and 21% of InaL block at Cmax. By applying the same block effect for Ikr and InaL in our model, the simulation showed similar trends as the clinical trial data, i.e. the prolongation of the QT and TpTe interval, and slight decrease of JTp interval on simulated surface ECG. This is an interesting verification for the clinical trial ECG measurements, and a good match of clinical and physiological modeling results.
Another factor for the modeling simulation is to set the transmural dispersion of the ventricle, from endocardium to epicardium layers. In our model, the dispersion could be set with different ion channel conductance from layer to layer as we did in the previous studies [8] [15] . However, we ignored the transmural dispersion in this study for simplicity purposes. More experiments of dispersions can be conducted in later studies.
It looks like JTp can be a useful addition to the QT interval for assessing the cardiac effect of drugs. However, detection of T peak is not a trivial task as indicated in the method section. Therefore, adding another 'controversial' ECG parameter detection to an already complicated detection of the end of T wave is not ideal from a signal processing point of view, and may not be ideal from a clinical practice point of view either. Our approach of detecting the T peak is the same as our method of detecting the T end, making it as robust and global as possible. That is why we tried to avoid any lead-by-lead approach, and instead, used a global composite lead, like the VM. When T wave morphology gets complicated as a plateau or notch appears, our method takes the center of the T wave plateau region, which is more robust than simply picking the maximum point of T wave. This T peak measurement has been verified by our modeling simulation to better reflect transmural dispersion than the maximum point of T wave [8] .
For the future research of modeling multi-ion channel effects on ECG, we would like to try different ion channel models and with different dispersion experiments.
